Intranasal Corticosteroids Market Report 2026

The intranasal corticosteroids market size has grown strongly in recent years. It will grow from $6.78 billion in 2025 to $7.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to limited awareness of intranasal corticosteroids, reliance on hospital pharmacies for drug distribution, growing incidence of nasal allergies, preference for conventional treatment methods, restricted online pharmacy access.

The intranasal corticosteroids market size is expected to see strong growth in the next few years. It will grow to $9.74 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing healthcare awareness, growth of retail and online pharmacies, rising incidence of chronic rhinitis and nasal polyps, adoption of combination therapies, development of patient-friendly spray devices. Major trends in the forecast period include rising prevalence of allergic rhinitis and nasal disorders, increasing adoption of prescription intranasal corticosteroids, growth in over-the-counter intranasal corticosteroid use, expansion of hospital and homecare distribution channels, focus on patient-centric treatment and ease of administration.

The increasing prevalence of allergic rhinitis is expected to drive growth in the intranasal corticosteroids market in the coming years. Allergic rhinitis is an allergic reaction that causes inflammation of the nasal passages, typically triggered by airborne allergens such as pollen, dust mites, mold, or pet dander. Its rising prevalence is mainly attributed to increasing environmental pollution, which exposes individuals to allergens and irritants that provoke nasal inflammation. Intranasal corticosteroids help manage allergic rhinitis by reducing inflammation in the nasal passages, alleviating symptoms such as sneezing, congestion, and runny nose. For example, in October 2023, the National Library of Medicine, a U.S.-based biomedical library, reported that allergic rhinitis affects more than 400 million people worldwide, with prevalence rates estimated at 10% to 30% among adults and over 40% in children. This indicates that the growing prevalence of allergic rhinitis is fueling the intranasal corticosteroids market.

Leading companies in the intranasal corticosteroids market are focusing on developing innovative formulations, such as nasal sprays, to enhance targeted delivery and improve patient adherence. Nasal sprays are liquid medications administered directly into the nose via a spray nozzle to treat conditions like allergies, congestion, or inflammation. They provide rapid drug absorption through the nasal mucosa, offering quick relief with minimal systemic effects. For instance, in March 2024, OptiNose Inc., a U.S.-based pharmaceutical company, received FDA approval for XHANCE, the first and only treatment specifically indicated for adults with chronic rhinosinusitis (CRS) without nasal polyps. This nasal spray employs a unique exhalation delivery system that allows the medication to reach deep into the nasal cavity, effectively treating CRS with or without nasal polyps in adults. Each spray delivers 93 mcg of fluticasone propionate, and the device operates by having the user exhale into a mouthpiece while simultaneously releasing the spray into the nostril, ensuring precise delivery and improved symptom relief.

In April 2023, SK Capital Partners LP, a U.S.-based investment firm, acquired Apotex for an undisclosed amount. Through this acquisition, SK Capital Partners aims to strengthen Apotex’s global presence in affordable pharmaceuticals by investing in its growth, operational efficiency, and product innovation. Apotex Inc., a Canada-based company, manufactures intranasal corticosteroid sprays.

Major companies operating in the intranasal corticosteroids market are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Haleon plc, Intas Pharmaceuticals Limited, Organon Pharma (UK) Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Limited, Cipla Ltd., Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, OptiNose US Inc., Taro Pharmaceutical Industries Ltd., Maya Biotech Private Limited, AdvaCare Pharma USA, Lupin Ltd., Xenone Healthcare Private Limited.

North America was the largest region in the intranasal corticosteroids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intranasal corticosteroids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intranasal corticosteroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the intranasal corticosteroids market by increasing the cost of imported active pharmaceutical ingredients (APIs) and packaging materials. Prescription and over-the-counter drug segments are particularly affected, with regions such as Asia-Pacific and Europe experiencing higher import duties. These tariffs have led to higher production costs and pricing adjustments. On the positive side, tariffs are encouraging local API production, regional manufacturing, and supply chain diversification to reduce dependency on imports.

The intranasal corticosteroids market research report is one of a series of new reports that provides intranasal corticosteroids market statistics, including intranasal corticosteroids industry global market size, regional shares, competitors with a intranasal corticosteroids market share, detailed intranasal corticosteroids market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal corticosteroids industry. This intranasal corticosteroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intranasal corticosteroids are anti-inflammatory medications administered through the nose to manage conditions like allergic rhinitis and nasal polyps. They work by reducing swelling, congestion, and mucus production in the nasal passages, thereby improving breathing and alleviating allergy symptoms.

The main categories of intranasal corticosteroids include prescription drugs and over-the-counter drugs. Prescription intranasal corticosteroids are doctor-approved medications used for moderate to severe allergic rhinitis or chronic nasal inflammation, often chosen for long-term or specialized treatment under medical guidance. Their applications include allergic rhinitis, nasal polyps, sinusitis, and other related conditions. These drugs are distributed through various channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by multiple end users, including hospitals, clinics, homecare settings, and healthcare providers.

The intranasal corticosteroids market consists of sales of fluticasone propionate nasal spray, mometasone furoate nasal spray, budesonide nasal spray, beclomethasone dipropionate nasal spray, and triamcinolone acetonide nasal spray. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.